Business · 1 sources covering this

The market for psychedelic drugs to treat mental health conditions gets a big buy signal

Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 0 C · 1 R

How 1 sources are covering this

CNBCLean R·16h ago
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.
Read at CNBC →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/f9362e9b6ded158c974acc4b3e9d075949874645"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="The market for psychedelic drugs to treat mental health conditions gets a big buy signal"></iframe>

The market for psychedelic drugs to treat mental health conditions gets a big buy signal

How 1 sources are covering this

The market for psychedelic drugs to treat mental health conditions gets a big buy signal

More from Business

Oil Prices Cross $90 a Barrel as U.S.-Iran Conflict Widens

CNBC Daily Open: Burnham set to take helm of 'poverty stricken disaster,' says Trump

Stock futures are mixed after Wall Street suffers losing week: Live updates

TSMC is accelerating Arizona factory buildout to capitalize on AI 'megatrend,' CFO says

Reader

Trust & legal

Across the network